Pew Offers Support for Drug Management Programs in Prescription Drug Abuse and Prevention Act of 2015

Prescription Drug Abuse Prevention and Treatment Act of 2015 Support Letter

On June 4, Pew sent a letter to Senators Joe Manchin (D-WV), Angus King (I-ME), and Shelley Moore Capito (R-WV), offering support for select provisions in the Prescription Drug Abuse and Prevention Act of 2015. These provisions would allow Medicare Part D plan sponsors to require patients at risk of drug abuse to use pre-designated pharmacies and providers to obtain prescriptions for opioids and other controlled substances.

The Honorable Joe Manchin
United States Senate
Washington, DC 20510

The Honorable Angus King
United States Senate
Washington, DC 20510

The Honorable Shelley Moore Capito
United States Senate
Washington, DC 20510

Dear Senators Manchin, King, and Capito:

On behalf of The Pew Charitable Trusts, a nonpartisan, nonprofit research and policy organization, we are writing to express Pew’s support for Section 7 of the Prescription Drug Abuse Prevention and Treatment Act of 2015, which would allow Medicare Part D plan sponsors to require patients at risk of drug abuse to use pre-designated pharmacies and prescribers to obtain prescriptions for opioids and some additional controlled substances. These drug-management programs, which are also known as Patient Review and Restriction programs (PRRs), are a critical tool for addressing the national epidemic of prescription drug abuse.

PRRs can improve continuity of care among at-risk patients and provide improved drug therapy management. However, current law does not permit their use in Medicare. This legislation would authorize the use of PRRs in Medicare Part D, expanding the number of tools that are available to plan sponsors to combat prescription drug abuse. The legislation also includes beneficiary protections that would ensure patients with legitimate medical needs have access to effective pain control.

There is broad bipartisan, bicameral support for these programs as demonstrated by policy proposals put forward on both sides of the Capitol and in the FY 2016 Budget request for the Department of Health and Human Services. The breadth of this action reflects a shared interest in advancing this policy as an effective tool to decrease abuse of opioids and other controlled substances. Pew urges Congress to pass legislation that authorizes these programs in Medicare to help address the nation’s prescription drug abuse epidemic.

Pew thanks you for your work on this important public health policy and looks forward to working with Congress to advance legislation that maximizes the impact of PRRs and ensures the policy works as intended.

Sincerely,

Allan Coukell
Senior Director, Health Programs
The Pew Charitable Trusts

Cynthia Reilly
Director, Prescription Drug Abuse
The Pew Charitable Trusts

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.